Organovo Holdings Inc(NYSEMKT:ONVO) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Jun 9, 2016. Company reported revenue of $548.00K. Analysts estimated a revenue of $300.00K. Earnings per share were $-0.09. Analysts had estimated an EPS of $-0.11.
Several Insider Transactions has been reported to the SEC. On Sep 23, 2015, Robert Jr. Baltera (director) sold 6,000 shares at $4.03 per share price.Also, On Aug 13, 2015, James T Glover (director) purchased 10,000 shares at $2.80 per share price.On Aug 13, 2015, Keith Murphy (CEO) purchased 20,000 shares at $2.56 per share price, according to the Form-4 filing with the securities and exchange commission.
Organovo Holdings Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development biological research and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition architecture and function. Its platform NovoGen Bioprinters is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue which can be used for predictive preclinical testing of drug compounds.